Dr. Urano did NOT mention Amarantus in his blog today. He is working with many drugs and companies. His "small molecule" method is designed to stimulate the natural production of MANF within the body to cure wolframs rather than use injections of recombinant MANF, which is our patent. Urano is saying he prefers the "small molecule" method at the moment. That doesn't suggest to me that any "breakthrough" for wolframs he may announce soon will involve us.

Our MANF patent for wolframs and diabetes seems to have been put on the back burner for now.

He may be using our MANF patent for the "eye" however. But the way I'm reading his blogs our MANF patent is taking a back seat to the "small molecule" method for wolframs and diabetes.

According to postgost on Yahoo, he thinks the "small molecule" method may introduce toxicity, thus the reason Urano said he prefers it "for the moment."
Maybe Urano is hoping to avoid the toxicity.